Could cause temporary or reversible harm; serious harm is unlikely.
Presence of Foreign Substance; Product complaints received related to brownish/blackish stains on the tablets and brownish/blackish powder observed inside the bottles.
| Brand name | LISINOPRIL AND HYDROCHLOROTHIAZIDE |
| Generic name | LISINOPRIL AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, LISINOPRIL |
| Distributed by / for | Lupin Pharmaceuticals Inc. |
| NDC | 68180-518-01 |
| Full product label | Lisinopril and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg, 100 tablet bottle, Rx only, Manufactured by for: Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by: Lupin Limited, Pithampur, INDIA NDC 68180-518-01 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to wholesalers/distributors and supermarket and drug chains throughout the United States. |
| Quantity | 39,216 bottles |
| Recall initiated | 2019-07-17 |
| Report date | 2019-08-21 |
| Recall completed | 2020-09-14 |
| Recall number | D-1720-2019 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗